Ledger.Open graph →
SEC Form D · filed July 29, 2022

Renibus Therapeutics, Inc

Offering
$20.0M
Sold
$14.9M
Exemption
Rule 506(b)
Industry
Pharmaceuticals
Location
SOUTHLAKE, TX
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (18)

D. J. Keyser · Southlake, TXExec · DirectorHenrik J. Rasmussen · Southlake, TXDirectorBhupinder J. Singh · Southlake, TXExec · DirectorJamie J. Donadio · Southlake, TXExecFrank J. Stonebanks · Southlake, TXExec · DirectorCarlos Guillem · Southlake, TXDirectorMarshall H. Durston · Jackson, WYDirectorGregory S. Leadholm · Chicago, ILExecRobert K. Grunewald · Jackson, WYExec · DirectorAdam Edelman · Boulder, COExec · DirectorPete K. Fawcett · Chicago, ILDirectorRyan K. Ripp · Jackson, WYExec · DirectorLisa Henthorne · Quebec City, Quebec, CanadaExec · DirectorRichard Hoel · Quebec City, Quebec, CanadaDirectorLouis Veronneau · Quebec City, Quebec, CanadaExec · DirectorPotrero Capital Research, LLC · SAN FRANCISCO, CAExec · DirectorRobert Holt · Bozeman, MTDirectorPeter Strom · Bozeman, MTExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗